Gastric absorption of oral paracetamol (acetaminophen) may be unreliable perioperatively in the starved and stressed patient. We compared plasma concentrations of parenteral paracetamol given preoperatively and oral paracetamol when given as premedication.
Paracetamol (acetaminophen) is a key part of perioperative acute pain management. Previous studies have studied proparacetamol rather than paracetamol as an intravenous (IV) preparation [1] [2] [3] . It is an established drug for premedication and is opioid-sparing 4, 5 . Given orally, it is well absorbed from the proximal small bowel and is not subject to significant first-pass metabolism in the liver. The therapeutic range for paracetamol is not well established but the lower end of the range is widely accepted to be 10 mg.l - 1 6,7 . Good oral bioavailability is estimated at between 63 to 89% in adults 8 .
However, gastric emptying may be delayed perioperatively, so absorption of oral paracetamol may be unreliable 9 . In fact, oral paracetamol absorption is used as a marker in gastroenterology to determine the rate of gastric emptying 10 . As well as uncertainty about absorption, there are also difficulties with the timing of oral premedication, which may make IV paracetamol a better route perioperatively 11 . The onset of analgesic action is important when studying the clinical efficacy of analgesics, especially in the management of postoperative pain 12 . In our hospital we use paracetamol routinely in day case surgery, as do many other hospitals, but if oral doses are not achieving therapeutic concentrations, then patients are not getting optimal care 13 . Intravenous paracetamol may be better, but is also more expensive. Oral paracetamol costs less than £0.01 for 1.0 g while IV paracetamol is around £1.50 (A$2.54/€1.77/ US$2.11) 14 . The aim of this study was to compare plasma concentrations of paracetamol given intravenously or orally as preoperative analgesia. We wished to establish whether the IV preparation, the oral preparation or both achieve therapeutic plasma concentrations perioperatively and if so, for how long these are maintained and what maximum plasma concentrations are achieved. Patients were approached preoperatively and received verbal and written information about the intention and nature of the study. Written informed consent was obtained from patients undergoing ear, nose and throat or an elective orthopaedic procedure.
Intravenous versus oral paracetamol as premedIcatIon
Our trial was performed over a two-year period that commenced on 7 April 2007 and ended on 26 February 2009. Patients with American Society of Anesthesiologists physical status I and II, between the ages of 16 and 75 years and booked for elective surgery were included. Exclusion criteria included patients refusing to participate in the study, who were unable to take an oral preparation, whose operations would take less than one hour, were already taking paracetamol either alone or in combination or who had taken it in the previous 12 hours, patients with a history of paracetamol allergy or any reaction to the drug, children under the age of 16, patients unable to understand or give consent, women who were pregnant or breastfeeding, patients with a history of complete nonresponsiveness to paracetamol, and patients with pancreatic disease in the previous 12 months or with impaired liver or kidney function.
Treatments were allocated randomly by blinded draw of lots. The oral group received paracetamol 1.0 g 30 minutes before scheduled surgery and the IV group a dose of 1.0 g immediately before induction of anaesthesia. All patients were given a standardised anaesthetic by the same specialist anaesthetist. This was an open study and the anaesthetist was not blinded to the intervention. Routine monitoring started in the anaesthetic room. An IV catheter was inserted into one arm for induction of anaesthesia and a second in the opposite arm for collection of blood samples. Anaesthesia was induced and maintained with IV opioid, propofol and volatile agent according to the requirement of the patient. A blood sample was collected 30 minutes after the dose was given in the oral group and 30 minutes after the IV dose was administered in the IV group, then at intervals of 30 minutes for 240 minutes after the initial dose. All identifiable information was removed and the specimens were sent to the laboratory.
A prospective power analysis indicated 47 patients in each group were required to detect a clinically significant difference in the proportion of patients who achieved therapeutic levels (two-sided test of proportions, 90% power, alpha=0.05, assuming IV group proportion=0.9 and difference to detect=0.2). Allowing for some withdrawals or exclusions, we aimed for 55 patients in each group.
Biochemical analysis
Lithium heparinised plasma, with a sample volume of 5 µl, was separated and stored at -20°C. Supplier data indicates separated serum is stable for 48 hours when stored between 2 and 8°C. All samples were assayed within this time frame, and all samples on an individual patient were assayed at the same time within 48 hours of receipt in the laboratory. Plasma paracetamol concentrations were determined using a Beckman Coulter Unicel DxC 800 system. This is a particle-enhanced turbidimetric inhibition immunoassay, with the reaction monitored at 340 nm. Haemolysis, lipaemia and icterus do not interfere with the assay. The assay was calibrated using Beckman Coulter Drug Calibrator 2. Routine internal quality control was by Beckman Coulter Triad NYSSPATH levels 1, 2 and 3.
The lower limit of detection reported by the laboratory for this study was 10 mg.l -1 .
Statistical analysis
Data analyses were undertaken using the JMP Ver. 8 (SAS Inc., USA) software and StatsDirect Ver. 2.7.7 (StatsDirect Ltd, UK) softwares. Differences in proportions were compared using Fisher's exact test. Continuous measures were compared by twotailed t-test, except C max compared using the nonparametric Wilcoxon's rank sum test. Correlations with C max are the non-parametric Spearman's rank correlation coefficient (r s ). Lines of best fit for dose versus C max plots were unsophisticated approximations using linear regression and substituting C max of 5 mg.l -1 when C max was <10 mg l -1 .
RESULTS
Three patients were withdrawn from the oral group: one by request, one because the premedication dose was not given and one was given IV paracetamol in error. Two patients from the IV group were underweight (less than 50 kg), one patient had taken paracetamol in the preceding 12 hours and another patient received an extra dose of paracetamol during the study period. After these exclusions data from 106 patients were analysed: 52 oral and 54 IV. No side-effects of paracetamol treatment were observed in either group.
Overall, the patients in the two treatment groups were very similar in distribution of age, weight and gender (Table 1) . Dose in the two groups are also comparable but C max differ ( Table 2) .
Concentration versus time curves were plotted for each study group (Figure 1 ). C max for IV paracetamol (19 mg.l -1 ) was considerably greater than for oral paracetamol (13 mg.l -1 ), P <0.0001. Median T max was 30 minutes for both groups and not informative for this study. Intravenous paracetamol resulted in therapeutic levels for a median time of three hours, whereas for oral administration this was less than 1.5 hours. Intravenous concentration was greater (P <0.01) until 3.5 hours.
The proportion of patients with any therapeutic concentration of paracetamol was also markedly different between the groups (Figure 2 and Table 3 ). Only 67% of the oral group achieved concentrations at therapeutic levels at any time in the study compared to 96% of the IV group (P <0.0001). The percentage of IV patients with therapeutic levels was never lower than the oral group for the entire 240 minute study period.
There was a weak positive correlation between patient age and C max (IV r s =0.25, P=0.07; oral r s =0.33, P=0.02) and some evidence of a negative correlation of weight to C max (IV r s =-0.73, P <0.0001; Oral r s =-0.37, P=0.007). Correlations of dose (mg per kg) to C max are identical to weight but are positive. Because there were patients who did not achieve any concentration more than 10 mg.l -1 and consequently C max is not precisely known for them, these data do not facilitate accurate linear regression. Nevertheless, by arbitrarily assuming C max equals 5 mg.l -1 for those individuals, we estimate from an approximate line of best fit (Figure 3 ) that an oral paracetamol dose of 20 mg.kg -1 is necessary to achieve a C max of 19 mg.l -1 (the median C max achieved by IV paracetamol). Accordingly we conclude there is evidence that for 50 kg, 75 kg and 100 kg individuals, an effective IV equivalent oral paracetamol dose would be 1.0 g, 1.5 g and 2.0 g respectively. Patients who weigh more than 120 kg may need a higher IV dose if looking at a per kg dose. Data presented in Figure 3 may support a higher IV dose, as a dose of 7 to 8 mg.kg -1 in these patients resulted in a sub-therapeutic plasma level according to the linear regression line, but there were only a small number of patients over 120 kg in both study groups and our numbers are too small to make these conclusions. A dose of more than 1.0 g does not fall into the current licensing laws for IV paracetamol in the United Kingdom.
DISCUSSION
In this randomised controlled trial of preoperative analgesia, we measured and compared plasma paracetamol concentrations following oral and IV dosage. We wanted to know whether therapeutic levels were reached in the stressed and starved patient 15 . The IV route produced higher concentrations throughout the study period, though the difference in plasma levels between the two groups was less significant from 150 minutes onwards in those patients who achieved therapeutic plasma levels. A pilot study 1 compared IV proparacetamol and oral paracetamol and produced similar results to our work. Pro-paracetamol is comparable with IV paracetamol 16 but the work published with IV paracetamol is limited. Intravenous paracetamol is effective and safe 17 and has a better safety profile than its prodrug, proparacetamol 18 . The effect compartment paracetamol concentration cannot be measured but is related to the cerebrospinal fluid concentration which lags behind plasma concentration. Passage through the bloodbrain barrier could be concentration dependent 2 . Paracetamol undergoes first-order absorption and elimination and for these drugs, maximum plasma paracetamol concentration is directly proportional to dose 19 . Drug effect is usually attributed to the total area under the concentration versus time curve, but analgesic studies suggest that the peak concentration may also be important for the analgesic effect [20] [21] [22] .
There are some limitations to our study. The lowest plasma concentration measured by the assay was 10 mg.l -1 , which is accepted as the lower concentration of the therapeutic analgesic range 4, 5, 12, 19, 23 and for antipyresis 24 . However, the plasma concentration required for analgesic effect may be even higher than this 1, 20, 23 . It might have been useful to have the actual values below 10 mg.l -1 for statistical analysis, but it would not be of clinical significance if those levels where sub-therapeutic. Since our study, new recommendations for paracetamol use have been introduced at our hospital. These allow preoperative loading doses of 1.5 g oral paracetamol if the patient weighs 50 to 75 kg; and 2.0 g if the weight is greater than 75 kg. For the first postoperative 24 hours, a total daily dose of 5.0 g is permitted in order to allow plasma concentrations to be maintained. In support of higher dose oral paracetamol, a study looking at reduction of postoperative morphine requirement used an oral paracetamol dose regimen of 6.0 g in 24 hours 25 . A future study examining paracetamol plasma levels after a higher oral dose of 1.5 g or 2.0 g compared with an IV loading dose, in association with postoperative pain scores and including time to rescue analgesia and postoperative opioid consumption, might be useful in establishing the role of paracetamol as premedication 21 . 
